Keryx Biopharmaceuticals News

Keryx Biopharmaceuticals, Inc. today announced updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc.

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the FDA has granted Fast Track designation for the company's PI3K/Akt pathway inhibitor compound, perifosine , for the treatment of relapsed/refractory multiple myeloma.

Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.

AEterna Zentaris' Anti-Cancer Compound, Perifosine , Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma QUEBEC CITY , Dec.

The 51 st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine at 51st Annual Meeting of the American Society of Hematology Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov.

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 in combination with bortezomib has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology , to be held in New Orleans from December 5-8, 2009.

Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease , today announced its results for the third quarter ended September 30, 2009.

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

Four minutes from now, you and I are going to make a bet -- and I can virtually guarantee you will lose.

KERX) dip down towards the $2 mark, it may be a good time to accumulate for the long term; especially if the price of the stock were to dip below the $2 mark.

Keryx Biopharmaceuticals, Inc. today announced that an abstract related to the clinical data of the 55-patient Phase 2 high-dose study of Zerenex has been accepted for presentation during the poster sessions to be held at the upcoming American Society of Nephrology Renal Week Meeting and exposition taking place October 27-November 1 in San Diego, ...

We have a large pool of in-house financial professionals, a wide array of research platforms and a dedicated team that combined would bring enhanced knowledge and first-hand information that would help you manage your understanding of the market.

When a stock's share price is lower than the mercury in a thermometer in North Dakota in February, investors tend to give it the cold shoulder.

Many investors are gloating pretty loudly about their investment performance over the past year.

Disney buys Marvel. David Gardner's top stock jumps 1,334%! See what David recommends that you buy NEXT.

Shares of Keryx Biopharmaceuticals spiked as high as $1.46 on Thursday morning after the company announced the initiation of another Phase II study for Perifosine, this time to measure the drug's effectiveness in treating relapsed or refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma .

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma .